# Bone Marrow Grafting and Cellular Therapy for Leukemia and Lymphoma

> **NIH NIH P01** · STANFORD UNIVERSITY · 2022 · $2,680,780

## Abstract

Overall Program Project Grant: Project Summary/Abstract
Hematopoietic cell transplantation (HCT) is an effective therapy for a broad range of hematological malignances
and represents the first successful, widely applied cellular therapy for cancer. The mechanisms of improved
outcomes are focused on hematopoietic and immunological engraftment from the donor to the recipient, resulting
in graft vs tumor effects and immunological reconstitution. However, several major challenges remain, including
immunological recognition and attack of the host termed graft vs host disease (GVHD), immunological
incompetence resulting in frequent opportunistic infections, reactivation of endogenous viruses and disease
relapse. We have made excellent progress in the prior funding period as detailed in the application. The overall
goals of our Program Project Grant are to develop a more robust fundamental understanding of transplantation
biology and address the major challenges of HCT including GVHD, disease relapse and immune reconstitution.
We will tackle these major challenges through innovative animal modeling, comprehensive biological and
molecular analysis, novel imaging of animal and human subjects and biologically focused translational clinical
trials. In addition, we will explore the biology of key cellular populations including Treg, iNKT, TR1, CD8 memory
and CAR T cells. Our Program involves 5 interactive Projects focusing on the biology and prevention of GVHD
through an enhanced understanding of cellular imaging and immune regulation (Projects 1 and 2), prevention
and treatment of disease relapse with memory CD8+ T cells and vaccination strategies (Project 3), improved
function and efficacy of CAR T cells (Project 4) and monoclonal antibody based strategies (Project 5). These
Projects are supported by three Cores (Administration and Clinical Trial Coordination, Biostatistics and Data
Management and Cell Processing and Immune Monitoring). Through our interactive Program Project, we will
gain novel insights into the biology of hematopoietic cell transplantation and develop innovative strategies to
improve outcomes for patients with hematological malignancies. The knowledge gained has profound
implications for cancer and transplantation biology and also for the treatment of patients with a broad range of
immunological conditions such as autoimmune disorders and transplantation of solid organs.

## Key facts

- **NIH application ID:** 10475717
- **Project number:** 5P01CA049605-32
- **Recipient organization:** STANFORD UNIVERSITY
- **Principal Investigator:** Robert S Negrin
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $2,680,780
- **Award type:** 5
- **Project period:** 1997-05-01 → 2024-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10475717

## Citation

> US National Institutes of Health, RePORTER application 10475717, Bone Marrow Grafting and Cellular Therapy for Leukemia and Lymphoma (5P01CA049605-32). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10475717. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*